Post-thrombotic syndrome is an independent determinant of health-related quality of life following both first proximal and distal deep vein thrombosis

Q: What is the clinical evidence from this study?

Population: Refractory diffuse large B-cell lymphoma (n=30). Intervention: 90Y-ibritumomab tiuxetan plus BEAM and autologous stem cell transplantation. Primary outcome: Overall response rate at day +100 (95% CI 53.6-86.4).

Lara N. Roberts; Raj Patel; Nora Donaldson; Laura M. Bonner; Roopen Arya

doi:10.3324/haematol.2013.089870

January 17, 2014HaematologicaOpen Access

Post-thrombotic syndrome is an independent determinant of health-related quality of life following both first proximal and distal deep vein thrombosis

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Does the addition of 90Y-ibritumomab tiuxetan to BEAM conditioning chemotherapy improve response rates in patients with refractory diffuse large B-cell lymphoma undergoing autologous stem cell transplantation?

Structured PICO

Does the addition of 90Y-ibritumomab tiuxetan to BEAM conditioning chemotherapy improve response rates in patients with refractory diffuse large B-cell lymphoma undergoing autologous stem cell transplantation?

P

Population

30 patients aged 18 to 70 years with refractory diffuse large B-cell lymphoma were treated with 90Y-ibritumomab tiuxetan plus BEAM and autologous stem cell transplantation, with a median follow-up of 31 months.

I

Intervention

90Y-ibritumomab tiuxetan at a fixed dose of 0.4 mCi/kg (maximum dose 32 mCi) given 14 days prior to high-dose BEAM preparative chemotherapy (carmustine 300 mg/m2, etoposide 200 mg/m2, cytarabine 200 mg/m2, melphalan 140 mg/m2) followed by autologous stem cell transplantation (ASCT).

O

Outcome

Response rate after transplantation (evaluated 3 months after ASCT according to the 2007 Cheson criteria)surrogate

Limitations

Small sample size precluding definitive conclusions
Lack of a randomized control group
Potential underreporting of secondary myelodysplastic syndrome or acute myeloid leukemia due to symptom-driven bone marrow assessments
Low numbers of patients precluding definitive conclusions
Lack of comparative data (single-arm design)

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

The addition of 90Y-ibritumomab tiuxetan to BEAM conditioning before autologous stem cell transplantation is safe and yields a high response rate with promising survival in patients with refractory diffuse large B-cell lymphoma.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Roberts et al. (2014) studied Refractory diffuse large B-cell lymphoma (n=30). 90Y-ibritumomab tiuxetan plus BEAM and autologous stem cell transplantation was evaluated on Overall response rate at day +100 (95% CI 53.6-86.4).

synapsesocial.com/papers/6a959a9957dad826d8f5b6b6 https://doi.org/10.3324/haematol.2013.089870

View Full Paper

Ask AI

Bookmark

Share

Post-thrombotic syndrome is an independent determinant of health-related quality of life following both first proximal and distal deep vein thrombosis

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Post-thrombotic syndrome is an independent determinant of health-related quality of life following both first proximal and distal deep vein thrombosis

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading